The discrepancy between the beneficial effects on glucose metabolism, inflammation and atherosclerosis, and no direct effect on the risk of type II diabetes and cardiovascular disease, and increased mortality across several diseases, has been mentioned as the adiponectin paradox [23]. Here, ADIPOQ is linked to cardiovascular disorder.